Skip to main content
Log in

Evaluation of the therapeutic effect of TAE on primary liver cancer

  • Clinical Aspects in the Treatment for Operable and Session II. Chemotherapy and Radiotherapy II. 1. TAE-1
  • Primary Liver Cancer, Transcatheter Arterial Chemoembolization, Therapeutic Effect
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The therapeutic effect of transcatheter arterial chemoembolization (TAE) performed on 31 patients with primary liver cancer was evaluated using the following procedures: (1) the alpha-fetoprotein (AFP) reduction rates and prognoses were analyzed according to the tumor reduction rates (TR), and (2) the AFP reduction rates and prognoses were also analyzed according to the tumor necrosis rates (TN) estimated by regarding every region with Lipiodol retention as being necrotic. The following results were obtained. The AFP level was 400 ng/ml or higher in 15 patients (48%). Their AFP reduction rates were as favorably high as 65.4%–99.8% (mean, 88.1%), and the AFP level was normalized in 3 patients. The cumulative survival rates after the initial treatment were relatively high, i.e., 78.4% in the 1 st year, 58.1% in the 2nd year, and 38.7% in the 3rd year. These results suggested the effectiveness of the TAE treatment undertaken in this study. Regarding the TR, the tumor was reduced in size by 50% or more in only 5 patients (16%), and most patients had a TR of less than 25%. On the other hand, the majority, 25 patients (81%), had a TN ranging between 50% and less than 100%, including 7 who had a TN ranging between 50% and less than 90% and 18 who had a TN ranging between 90% and less than 100%. There was no significant correlation between the AFP reduction rate and the TN or TR. Regarding evaluation of the cumulative survival rates by TR and TN, the 1-year survival rate was lower in patients having a TR of less than 25% than in those having a TR of 25% or more. Patients having a TN of less than 50% showed a poor outcome as compared with those having a TN of 50% or more. Although the TR was found to be less than 50% in a majority of the patients when the therapeutic effect of TAE on the liver cancer was evaluated according to the TR, many of these patients showed a good outocome. Thus, the conventional efficacy evaluation, in which a tumor reduction of 50% or more is considered to be effective, should be reconsidered. On the other hand, the TN was found to be 50% or more in most of the patients suggesting the necessity of a more detailed classification of TN. In relation to the survival rate patients having a TN of less than 50% showed a poor outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Goldstein HM, Wallace S, Anderson JH, Bree RL, Gianturco C (1976) Transcatheter occulusion of abdominal tumors. Radiology 120:539

    Google Scholar 

  2. Japan Society for Cancer Therapy (1993) Criteria, for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28:101

    Google Scholar 

  3. Jinno K, Moriwaki S, Tanada M, Wada T, Mandai K, Okada Y (1992) Clinicopathological study on combination therapy consisting of arterial infusion of Lipiodol-dissolved SMANCS and transchatheter arterial embolization for hepatocellular carcinoma. cancer Chemother Pharmacol 31 [Suppl I]:S7

    Google Scholar 

  4. Kanematsu T, Furuta T, Takenaka K Matsumata T, Yoshida Y, Nishizaki T, Hasuo K, Sugimachi K (1989) A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 10:98

    Google Scholar 

  5. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C, Sakata Y, Shimamura Y, Jinno K, Takahashi A, Takayasu K, Tamura K, Nagasue N, Nakanishi Y, Makino M, Masuzawa M, Mikuriya S, Monden M, Yumoto Y, Mori T, Oda T, Cooperative Study Group for Liver Cancer Treatment of Japan (1992) Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma — a comparison of Lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study). Cancer Chemother Pharmacol 31 [Suppl I]:S1

    Google Scholar 

  6. Lotze MT (1987) Surgical management of hepatocellular carcinoma. Gastroenterol Clin North Am 16:613

    Google Scholar 

  7. Monden M, Sakon M, Gotoh M, Kanai T, Umeshita K, Wang KS, Sakurai M, Kuroda C, Okamura J, Mori T (1992) Selection of therapeutic modalities for hepatocellular carcinoma in patients with multiple hepatic lesions. Cancer Chemother Pharmacol 31 [Suppl I]:S38

    Google Scholar 

  8. Nakashima T (1976) Vascular changes and hemodynamics in hepatocellular carcinoma. In: Okuda K (ed) Hepatocellular carcinoma. J Wiley and Sons, New York, p 169

    Google Scholar 

  9. Okazaki N, Yoshida T, Yoshino M, Okada S, Shimada Y, Moriyama M, Takayasu K (1991) Changes in mode of response to chemotherapy for hepatocellular carcinoma induced by transarterial embolization. A case report. Jpn J Clin Oncol 21:69

    Google Scholar 

  10. Shimamura Y, Ishii M, Ono M, Makita F, Sekiguchi R, Yoshino M, Gunven P, Abe K (1992) Arterial infusion therapy: Lipiodol-cytostatics with and without embolization. In: Tobe T (ed) Primary liver cancer in Japan. Springer, Tokyo Berlin Heidelberg New York, p 273

    Google Scholar 

  11. Tanaka K, Nakamura S, Numata K, Okazaki H, Endo O, Inoue S, Takamura Y, Sugiyama M, Ohaki Y (1992) Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization. Radiology 185:457

    Google Scholar 

  12. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamada, T., Makita, F., Takehara, K. et al. Evaluation of the therapeutic effect of TAE on primary liver cancer. Cancer Chemother. Pharmacol. 33 (Suppl 1), S55–S59 (1994). https://doi.org/10.1007/BF00686669

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686669

Keywords

Navigation